The firm plans to use the proceeds to support commercial expansion in the US and EU, and for research, potential regulatory submissions, and general corporate purposes.

Gravity Diagnostics provides testing for toxicology, pharmacogenetics, infectious and upper respiratory diseases, blood diagnostics, and COVID-19.